Quick Answer
Nuvectis Pharma, Inc. reported Stockholders Equity of $18.41 million for fiscal year 2025.
Nuvectis Pharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $18.41M | +89.6% |
| 2024 | $9.71M | -20.4% |
| 2023 | $12.20M | -14.2% |
| 2022 | $14.22M | +229.2% |
| 2021 | -$11.01M | -109980.0% |
| 2020 | -$10.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $24.01M | +118.5% | +42.3% |
| June 30, 2025 | $16.87M | +34.7% | -19.5% |
| March 31, 2025 | $20.95M | +49.4% | +115.7% |
| December 31, 2024 | $9.71M | -20.4% | -11.6% |
| September 30, 2024 | $10.99M | -34.1% | -12.3% |
| June 30, 2024 | $12.53M | -38.4% | -10.7% |
| March 31, 2024 | $14.02M | +14.2% | +14.9% |
| December 31, 2023 | $12.20M | -14.2% | -26.9% |
- Nuvectis Pharma, Inc. showed an increase of +89.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, Nuvectis Pharma, Inc.’s stockholders equity has grown by 184230.0% (from -$10.0 thousand to $18.41 million).
- The most recent figure is from Nuvectis Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: